← All indications
Purpura, Thrombocytopenic
Any form of purpura in which the PLATELET COUNT is decreased. Many forms are thought to be caused by immunological mechanisms.
Subtype terms (2)
More specific conditions that are subtypes of Purpura, Thrombocytopenic in the MeSH hierarchy.
- Purpura, Thrombocytopenic, Idiopathic
106 drugs (70 approved, 36 experimental)
- Purpura, Thrombotic Thrombocytopenic
19 drugs (15 approved, 4 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (2)
Phase 3 trials (1)
Phase 2 trials (3)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (20)
- CSL Behring
- Amgen
- GlaxoSmithKline
- Huazhong University of Science and Technology
- Anhui Medical University
- Mahidol University
- Norwegian University of Science and Technology
- Shanxi Medical University
- Xinjiang Medical University
- Assiut University
- Zhejiang Chinese Medical University
- Shandong University
- Tsinghua University
- University of Vienna
- Jiao Tong University
- Medical University of Vienna
- Samodzielny Publiczny Szpital
- Shandong University of Traditional Chinese Medicine
- China Medical University
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (90)
- Ablynx
- Eisai
- Shire
- Bio Products Laboratory
- Roche
- CSL
- Genentech
- Octapharma
- Grifols
- Sanofi
- Biogen
- Novartis
- Anthera Pharmaceuticals
- Baxalta
- Bayer
- Hamilton Health Sciences Corporation
- Hengrui Therapeutics, Inc.
- Kissei Pharmaceuticals
- Kyowa Hakko Kirin
- Rigel Pharmaceuticals
- Sunshine Lake Pharma Co., Ltd.
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- University of Pittsburgh
- Pakistan Army
- Case Western Reserve University
- Cornell University
- Harvard University
- Duke University
- +60 more
Organization Involved with Phase 2 Indications (42)
- Swedish Orphan Biovitrum
- Bristol-Myers Squibb
- Immunomedics
- AstraZeneca
- Archemix Corp.
- PhytoHealth Corporation
- Symphogen A/S
- Iltoo Pharma
- Principia Biopharma, Inc.
- Fondazione Progetto Ematologia
- Aarhus University
- Changhua Christian Hospital
- University of London
- China Academy of Chinese Medical Sciences
- Etablissement Français du Sang
- Glaser Pediatric Research Network
- Hematology and Oncology Specialists
- Kaohsiung Medical University
- Katholieke Universiteit Leuven
- Kunming Medical University
- National Cheng Kung University
- Icahn School of Medicine at Mount Sinai
- Tianjin Medical University
- National Taiwan University
- Momenta Pharmaceuticals
- Lee's Pharmaceutical
- Henan Medical University
- San Bortolo Hospital, Vicenza
- Werlhoff Institut Hannover, Germany
- University of Alabama, Birmingham
- +12 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (3)